Washington will pay partners $ 1.95 billion upon delivery of these 100 million doses. The deal also gives the government the ability to purchase an additional 500 million doses. Note that on Monday, the two companies announced a similar (albeit smaller) deal with the UK government.
Pfizer and BioNtech are currently conducting a Phase 1/2 clinical trial for coronavirus vaccine candidates in the BNT162 program, and they recently published positive study data for BNT162b1 – the most advanced of the group. Additionally, healthcare companies plan to start a Phase 2b / 3 clinical trial by the end of July, pending regulatory approval. This study is expected to recruit up to 30,000 healthy participants and test the safety and efficacy of the chosen vaccine candidate. It should also be noted that the Food and Drug Administration has granted expedited designation to two of the program’s applicants, BNT162b1 and BNT162b2.
Pfizer and BioNtech aren’t the only ones trying to develop mRNA-based COVID-19 vaccines – Modern (NASDAQ: ARNM) so is it, and it is also well advanced in the development process. This biotechnology company plans to start a phase 3 clinical trial on July 27 for its lead candidate, mRNA-1273. The pivotal study will bring together approximately 30,000 participants and its main objective will be “the prevention of the symptomatic disease of COVID-19”. As global efforts to find a vaccine intensify, the next few months will be crucial for Pfizer and BioNtech.